

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 February 2022 (17.02.2022)



(10) International Publication Number
WO 2022/035859 A3

(51) International Patent Classification:
C12N 5/073 (2010.01) C12N 5/22 (2006.01)
C12N 5/16 (2006.01)

(21) International Application Number:
PCT/US2021/045388

(22) International Filing Date:
10 August 2021 (10.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/063,668 10 August 2020 (10.08.2020) US

(71) Applicant: ANGIOCRINE BIOSCIENCE, INC.
[US/US]; 11575 Sorrento Valley Road, Suite 217, San
Diego, CA 92121 (US).

(72) Inventors: GINSBERG, Michael, Daniel; 11575 Sorren-
to Valley Road, Suite 217, San Diego, CA 92121 (US).
LANDEEN, Lee; 11575 Sorrento Valley Road, Suite 217,

San Diego, CA 92121 (US). FINNEGAN, Paul, William;
11575 Sorrento Valley Road, Suite 217, San Diego, CA
92121 (US). FRASER, John, K.; 11575 Sorrento Valley
Road, Suite 217, San Diego, CA 92121 (US).

(74) Agent: GRIMES, Julia, Anne et al.; Grimes & Yvon LLP,
800 Third Avenue, 28th Floor, New York, NY 10022 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

(54) Title: CRYOPRESERVED ENDOTHELIAL CELL COMPOSITIONS




Fig. 1

(57) Abstract: The present invention provides compositions comprising high densities of endothelial cells (such as human umbilical vein endothelial cells) in freezing media, methods of producing such compositions, and methods of using such compositions in the preparation of therapeutic endothelial cell compositions. Such compositions and methods provide numerous advantages including eliminating the requirement to remove cryopreservatives before administration of therapeutic endothelial cell compositions to human subjects and requiring minimal manipulations and human interventions before use in therapeutic methods.

[Continued on next page]

WO 2022/035859 A3

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

24 March 2022 (24.03.2022)